Crystalline forms of JAK1-selective inhibitor, processes for preparation and use thereof
The present disclosure relates to crystalline forms of JAK1-selective inhibitor, process for preparation and use for prevention and/or treatment of diseases associated with JAK family. The crystalline forms of the present disclosure show favorable properties such as simple preparation process, good stability, low hygroscopicity and good mechanical stability.
1. A crystalline form CS1 of Filgotinib, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 10.3°±0.2°, 13.7°±0.2° and 16.1°±0.2° using Cu-Kα radiation.
2. The crystalline form CS1 of Filgotinib according to claim 1 , wherein the X-ray powder diffraction pattern shows one or more characteristic peaks at 2theta values of 18.0°±0.2°, 21.7°±0.2° and 24.7°±0.2° using Cu-Kα radiation.
3. The crystalline form CS1 of Filgotinib according to claim 1 , wherein the X-ray powder diffraction pattern shows one or two characteristic peaks at 2theta values of 8.6°±0.2° and 19.4°±0.2° using Cu-Kα radiation.
4. A process for preparing crystalline form CS1 according to claim 1 , wherein the process comprises: suspending Filgotinib hydrochloride into halogenated aromatic hydrocarbons with adding base, stirring for crystallization at certain temperature, then isolating and drying the solid to obtain a halogenated aromatic hydrocarbon solvate and Form CS1 is obtained via a desolvation process by heating the halogenated aromatic hydrocarbon solvate.
5. The process for preparing crystalline form CS1 according to claim 4 , wherein said halogenated aromatic hydrocarbon is a solvent or a mixture of solvents selected from halogenated aromatic hydrocarbons; said base is inorganic base; said crystallization temperature is 25-0° C.; said desolvation temperature is 150-195° C.
6. A crystalline form CS2 of Filgotinib, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 17.5°±0.2°, 18.1°±0.2° and 8.0°±0.2° using Cu-Kα radiation.
7. The crystalline form CS2 of Filgotinib according to claim 6 , wherein the X-ray powder diffraction pattern shows 1 or more characteristic peaks at 2theta values of 24.7°±0.2°, 17.2°±0.2° and 27.4°±0.2°.
8. The crystalline form CS2 of Filgotinib according to claim 6 , wherein the X-ray powder diffraction pattern shows 1 or more characteristic peaks at 2theta values of 7.2°±0.2°, 11.0°±0.2° and 19.0°±0.2°.
9. A process for preparing crystalline form CS2 according to claim 6 , wherein the process comprises: suspending Filgotinib hydrochloride into carboxylic acid with adding base, stirring for crystallization at certain temperature, isolating and drying the solid to obtain a carboxylic acid solvate and crystalline form CS2 is obtained via a desolvation process by heating the carboxylic acid solvate.
10. The process for preparing crystalline form CS2 according to claim 9 , wherein said carboxylic acid is a carboxylic acid or a mixture carboxylic acid selected from C 1 -C 3 carboxylic acids; said base is inorganic base; said crystallization temperature is 25-0° C.; said desolvation temperature is 150-195° C.
11. A crystalline form CS3 of Filgotinib, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 11.8°±0.2°, 14.1°±0.2° and 17.8°±0.2° using Cu-Kα radiation.
12. The crystalline form CS3 of Filgotinib according to claim 11 , wherein the X-ray powder diffraction pattern shows 1 or more characteristic peaks at 2theta values of 18.4°±0.2°, 20.5°±0.2° and 22.9°±0.2°.
13. The crystalline form CS3 of Filgotinib according to claim 11 , wherein the X-ray powder diffraction pattern shows 1 or more characteristic peaks at 2theta values of 25.7±0.2°, 11.5°±0.2° and 23.6°±0.2°.
14. A process for preparing crystalline form CS3 according to claim 11 , wherein the process comprises: suspending Filgotinib hydrochloride into acetic acid with adding base, stirring for crystallization at certain temperature, isolating and drying to obtain Form CS3.
15. The process for preparing crystalline form CS3 according to claim 14 , wherein said base is inorganic base; said crystallization temperature is 25-0° C.
16. A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of crystalline form CS1 according to claim 1 , and pharmaceutically acceptable carriers or excipients.
17. A method of treating rheumatoid arthritis or Crohn's disease, comprising administering to a patient in need thereof a therapeutically effective amount of the crystalline form CS1 according to claim 1 .
18. A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of crystalline form CS2 according to claim 6 , and pharmaceutically acceptable carriers or excipients.
19. A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of crystalline form CS3 according to claim 11 , and pharmaceutically acceptable carriers or excipients.
20. A method of treating rheumatoid arthritis or Crohn's disease, comprising administering to a patient in need thereof a therapeutically effective amount of the crystalline form CS2 according to claim 6 .
21. A method of treating rheumatoid arthritis or Crohn's disease, comprising administering to a patient in need thereof a therapeutically effective amount of the crystalline form CS3 according to claim 11 .